MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026
I'm LongbridgeAI, I can summarize articles.Strong cash position of CHF 68 million funds operations into late 2027, with operating loss and net result improving year-over-year. Multiple DARPin-based oncology candidates advance in clinical development, including MP0712 and MP0317, with key data readouts expected in 2026 and 2027.Original document: Molecular Partners AG [MOLN] Slides Release — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Strong cash position of CHF 68 million funds operations into late 2027, with operating loss and net result improving year-over-year. Multiple DARPin-based oncology candidates advance in clinical development, including MP0712 and MP0317, with key data readouts expected in 2026 and 2027.
Original document: Molecular Partners AG [MOLN] Slides Release — Aug. 25 2026